| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14656566.7.17.2421 |
| P698 | PubMed publication ID | 17109616 |
| P50 | author | Christopher R Chapple | Q37831462 |
| P2860 | cites work | How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study | Q28202479 |
| Solifenacin significantly improves all symptoms of overactive bladder syndrome | Q30445725 | ||
| Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. | Q34543969 | ||
| Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial | Q34548769 | ||
| A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | Q46577111 | ||
| An epidemiological survey of overactive bladder symptoms in Japan | Q48525004 | ||
| Role of supraspinal tachykinins for micturition in conscious rats with and without bladder outlet obstruction. | Q50511768 | ||
| Employees with overactive bladder: work loss burden. | Q50761314 | ||
| Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. | Q51966491 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. | Q53342637 | ||
| Solifenacin demonstrates high absolute bioavailability in healthy men. | Q34549873 | ||
| Pharmacokinetics and safety of solifenacin succinate in healthy young men. | Q34550245 | ||
| Solifenacin in the management of the overactive bladder syndrome | Q34561081 | ||
| Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study | Q34562640 | ||
| Using anticholinergics to treat overactive bladder: the issue of treatment tolerability | Q34564933 | ||
| Diagnosis and treatment of the overactive bladder | Q35603079 | ||
| Describing bladder storage function: overactive bladder syndrome and detrusor overactivity | Q35603082 | ||
| Clinical and socioeconomic relevance of overactive bladder. | Q35687979 | ||
| Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder | Q35710439 | ||
| Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. | Q35838373 | ||
| Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly | Q36089662 | ||
| The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis | Q36122988 | ||
| Overactive bladder in the elderly: a guide to pharmacological management | Q36346373 | ||
| Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients | Q36362859 | ||
| Pathophysiology of overactive bladder | Q36399000 | ||
| Pharmacologic management of overactive bladder: practical options for the primary care physician | Q36399005 | ||
| Management of overactive bladder and urge urinary incontinence in the elderly patient | Q36399009 | ||
| Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence | Q39351514 | ||
| The cholinergic neurotransmitter system in human memory and dementia: a review | Q39756011 | ||
| Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study | Q40351748 | ||
| Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice | Q42142992 | ||
| Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity | Q42635966 | ||
| Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome | Q42648179 | ||
| Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis | Q42686754 | ||
| Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial | Q43310817 | ||
| A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials | Q43324239 | ||
| Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder | Q44035116 | ||
| Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial | Q44655032 | ||
| Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells | Q44683028 | ||
| Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder | Q44756641 | ||
| Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin | Q44910595 | ||
| In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. | Q44922103 | ||
| Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder | Q45148608 | ||
| Improved quality of life in patients with overactive bladder symptoms treated with solifenacin | Q45215936 | ||
| Health-related consequences of overactive bladder: an economic perspective | Q45235161 | ||
| Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program | Q46301443 | ||
| Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder | Q46535726 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2421-2434 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder | |
| P478 | volume | 7 |
| Q36307893 | A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials |
| Q57986078 | Muscarinic receptor MR signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells |
| Q37189382 | Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle |
Search more.